103 related articles for article (PubMed ID: 16638688)
1. Formulation, quality control and shelf life of the experimental cytostatic drug cyclopentenyl cytosine.
Schimmel K; Guchelaar HJ; van Kan E
Drug Dev Ind Pharm; 2006 Apr; 32(4):497-503. PubMed ID: 16638688
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of the experimental cytotoxic drug cyclopentenyl cytosine and its metabolite in plasma with HPLC tandem mass spectrometry.
Schimmel K; van Lenthe H; Leen R; Kulik W; Verschuur A; Guchelaar HJ; van Kuilenburg A
Biomed Chromatogr; 2008 Dec; 22(12):1368-73. PubMed ID: 18661479
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl.
Den Brok MW; Nuijen B; Meijer DM; Millán E; Manada C; Beijnen JH
PDA J Pharm Sci Technol; 2005; 59(4):246-57. PubMed ID: 16218203
[TBL] [Abstract][Full Text] [Related]
4. Measurement of cyclopentenyl cytosine 5'-triphosphate in vitro and in vivo by multidimensional high-performance liquid chromatography.
Agbaria R; Ford H; Kelley JA; Xie F; Politi P; Grem JL; Cooney DA; Marquez VE; Allegra CJ; Johns DG
Anal Biochem; 1993 Aug; 213(1):90-6. PubMed ID: 8238887
[TBL] [Abstract][Full Text] [Related]
5. The effect of cyclopentenyl cytosine on human SK-N-BE(2)-C neuroblastoma cells.
Slingerland RJ; Van Gennip AH; Bodlaender JM; Voûte PA; Van Kuilenburg AB
Biochem Pharmacol; 1995 Jul; 50(2):277-9. PubMed ID: 7632174
[TBL] [Abstract][Full Text] [Related]
6. Cyclopentenyl cytosine and neuroblastoma SK-N-BE(2)-C cell line cells.
Slingerland RJ; Van Gennip AH; Bodlaender JM; Voûte PA; Van Kuilenburg AB
Eur J Cancer; 1995; 31A(4):627-31. PubMed ID: 7576983
[TBL] [Abstract][Full Text] [Related]
7. Cellular pharmacology of cyclopentenyl cytosine in Molt-4 lymphoblasts.
Ford H; Cooney DA; Ahluwalia GS; Hao Z; Rommel ME; Hicks L; Dobyns KA; Tomaszewski JE; Johns DG
Cancer Res; 1991 Jul; 51(14):3733-40. PubMed ID: 1712247
[TBL] [Abstract][Full Text] [Related]
8. The cytostatic- and differentiation-inducing effects of cyclopentenyl cytosine on neuroblastoma cell lines.
Bierau J; van Gennip AH; Helleman J; van Kuilenburg AB
Biochem Pharmacol; 2001 Oct; 62(8):1099-105. PubMed ID: 11597578
[TBL] [Abstract][Full Text] [Related]
9. In situ cyclopentenyl cytosine infusion for the treatment of experimental brain tumors.
Viola JJ; Agbaria R; Walbridge S; Oshiro EM; Johns DG; Kelley JA; Oldfield EH; Ram Z
Cancer Res; 1995 Mar; 55(6):1306-9. PubMed ID: 7882327
[TBL] [Abstract][Full Text] [Related]
10. Reversal by cytidine of cyclopentenyl cytosine-induced toxicity in mice without compromise of antitumor activity.
Ford H; Driscoll JS; Hao Z; Dobyns KA; Rommel ME; Stowe E; Anderson JO; Plowman J; Waud WR; Johns DG
Biochem Pharmacol; 1995 Jan; 49(2):173-80. PubMed ID: 7840794
[TBL] [Abstract][Full Text] [Related]
11. Cyclopentenyl cytosine (CPEC): an overview of its in vitro and in vivo activity.
Schimmel KJ; Gelderblom H; Guchelaar HJ
Curr Cancer Drug Targets; 2007 Aug; 7(5):504-9. PubMed ID: 17691910
[TBL] [Abstract][Full Text] [Related]
12. Studies on the antitumor activity and biochemical actions of cyclopentenyl cytosine against human colon carcinoma HT-29 in vitro and in vivo.
Gharehbaghi K; Zhen W; Fritzer-Szekeres M; Szekeres T; Jayaram HN
Life Sci; 1999; 64(2):103-12. PubMed ID: 10069488
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9.
Jonkman-de Vries JD; Talsma H; Henrar RE; Kettenes-van den Bosch JJ; Bult A; Beijnen JH
Cancer Chemother Pharmacol; 1994; 34(5):416-22. PubMed ID: 8070009
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical development of a parenteral formulation of the investigational anticancer drug clanfenur.
Jonkman-de Vries JD; Van den Bemt BJ; ten Bokkel-Huinink WW; Underberg WJ; Kettenes-van den Bosch JJ; Henrar RE; Bult A; Beijnen JH
PDA J Pharm Sci Technol; 1997; 51(2):89-95. PubMed ID: 9146040
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P [6-11].
Jonkman-de Vries JD; Rosing H; Talsma H; Henrar RE; Kettenes-van den Bosch JJ; Bult A; Beijnen JH
Invest New Drugs; 1998; 16(2):99-111. PubMed ID: 9848573
[TBL] [Abstract][Full Text] [Related]
16. Absence of cardiotoxicity of the experimental cytotoxic drug cyclopentenyl cytosine (CPEC) in rats.
Schimmel K; Bennink R; de Bruin K; Leen R; Sand K; van den Hoff M; van Kuilenburg A; Vanderheyden JL; Steinmetz N; Pfaffendorf M; Verschuur A; Guchelaar HJ
Arch Toxicol; 2005 May; 79(5):268-76. PubMed ID: 15902424
[TBL] [Abstract][Full Text] [Related]
17. Primary packaging considerations in developing medicines for children: oral liquid and powder for constitution.
Campbell GA; Vallejo E
J Pharm Sci; 2015 Jan; 104(1):52-62. PubMed ID: 25393927
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280.
Bouma M; Nuijen B; Harms R; Rice JR; Nowotnik DP; Stewart DR; Jansen BA; van Zutphen S; Reedijk J; van Steenbergen MJ; Talsma H; Bult A; Beijnen JH
Drug Dev Ind Pharm; 2003 Oct; 29(9):981-95. PubMed ID: 14606662
[TBL] [Abstract][Full Text] [Related]
19. Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under in-use Conditions with Different Administration Materials.
Mueller C; Dietel E; Heynen SR; Nalenz H; Goldbach P; Mahler HC; Schmidt J; Grauschopf U; Schoenhamnmer K
Int J Pharm Compd; 2015; 19(3):261-7. PubMed ID: 26714367
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical development of a parenteral formulation of the novel anti-tumor agent carzelesin (U-80,244).
Jonkman-de Vries JD; de Graaff-Teulen MJ; Henrar RE; Kettenes-van den Bosch JJ; Bult A; Beijnen JH
Invest New Drugs; 1994; 12(4):303-14. PubMed ID: 7775131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
